ABL1 and Pleural effusion: Pleural effusion is mostly seen with BCR-ABL TKIs with dasatinib having a high likelihood of pleural effusion as the late toxicity.167 This was reported in the DASISION-dasatinib trial which reported a 10% incidence of pleural effusion in the 1st year, and 29% by the end of the study.